Nathanael Dolan, MD
Family Medicine · Carmi, ILNPI 1417183153
Payments from drug & device makers
Across 155 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$504
- AbbVie$384
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$234
- Lilly USA, LLC$149
- Johnson & Johnson$148
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$141
- plus $892 from 17 others
What the payments were for
- Food & beverage$2,452100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $504 |
| AbbVie(2 entities) | 30 | $384 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $234 |
| Lilly USA, LLC | 8 | $149 |
| Johnson & Johnson | 8 | $148 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $141 |
| GSK | 9 | $127 |
| Vanda Pharmaceuticals Inc. | 5 | $111 |
| Dexcom, Inc. | 6 | $98 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Pfizer | 5 | $71 |
| Novo Nordisk | 4 | $69 |
| Alkermes, Inc. | 2 | $58 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Exact Sciences | 1 | $21 |
| Electromed, Inc. | 4 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
How this compares
$2,452 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $49,533 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $46,812 |
| XareltoRivaroxaban | 25 | $35,536 |
| JardianceEmpagliflozin | 26 | $28,996 |
| EntrestoSacubitril/Valsartan | 24 | $22,550 |
| EliquisApixaban | 26 | $21,779 |
| FarxigaDapagliflozin Propanediol | 23 | $16,108 |
| JanuviaSitagliptin Phosphate | 13 | $14,933 |
| TradjentaLinagliptin | 21 | $14,033 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $11,994 |
| TrintellixVortioxetine Hydrobromide | 13 | $8,614 |
| Bydureon BciseExenatide Microspheres | 11 | $8,204 |
| LinzessLinaclotide | 16 | $7,894 |
| MyrbetriqMirabegron | 15 | $7,434 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 270 | $5,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $127 | $58,80586 claims |
| Novo NordiskOzempic | $69 | $49,53344 claims |
| Johnson & JohnsonXarelto | $148 | $35,53625 claims |
| PfizerEliquis, Dilantin | $71 | $23,62538 claims |
| AstraZenecaFarxiga | $504 | $16,10823 claims |
| AbbVieLinzess | $384 | $7,89416 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $1,12112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Carmi
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.